Source: Annual Congress 2001 - Rare and unusual diseases or problems



Rating:

Share or cite this content

Citations should be made in the following way:
B. Barbara, S. Centanni, F. Di Marco, M. Massarotti, C. Regorda, P. Carlucci, B. Marasini (Milan, Italy). DLCO change in systemic sclerosis patients after prostaglandin E1 infusion: preliminary data. Eur Respir J 2001; 16: Suppl. 31, 1528

Member's Comments

No comment yet.

Related content which might interest you: Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS trial Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 Fluid challenge test and pulmonary haemodynamics in patients with systemic sclerosis Source: International Congress 2017 – PAH and CTEPH Year: 2017 Quality of spirometry and diffusion of the lung (DLCO) data in patients with systemic sclerosis. Source: International Congress 2019 – Insights into physiological diagnostic services Year: 2019 Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Long-term outcomes in incident pulmonary arterial hypertension (PAH) patients initiated with triple combination therapy including parenteral prostacyclin (PGI2) Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020 Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis Source: Eur Respir J 2016; 48: 1658-1667 Year: 2016 Clinical feature of systemic sclerosis associated with pulmonary hypertension: results of one center study Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Plasma 6-ketoPGF1α, a stable metabolite of prostaglandin I2 shows a marked decrease in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 651s Year: 2006 Changes in FVC in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 The adoption of nintedanib in systemic sclerosis: the SENSCIS study Source: Breathe, 16 (2) 200005; 10.1183/20734735.0005-2020 Year: 2020 Pulmonary involvement and exercise limitation in patients with systemic sclerosis Source: Eur Respir J 2004; 24: Suppl. 48, 53s Year: 2004 Baseline profile of patients initiating sitaxentan for pulmonary arterial hypertension (PAH): preliminary results from thelin outcomes for patients surveillance (TOPS) Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Significance of pulmonary involvement in systemic sclerosis (SSc)– data from the German SSc-network Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 A preliminary study to identify correlations between blood glucose levels and cardiorespiratory observations in acute asthma patients receiving nebulised salbutamol. Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Effect of high or low-medium accumulated dose regimes of systemic corticosteroids for hospitalised patients with exacerbated chronic obstructive pulmonary disease: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data Year: 2021 Rapid switch from epoprostenol (EPO) to intravenous treprostinil (TRE) in patients with pulmonary arterial hypertension (PAH): safety, efficacy, and treatment satisfaction Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Expression of inflammatory cytokines following stepwise dose reduction of corticosteroids of long-term oral corticosteroids users with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 62s Year: 2004 The natural course of systemic sclerosis patients with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005 Protective effects of salmeterol on impeded alveolar-capillary gas transfer with saline infusion in COPD patients: preliminary results Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009